Tort Reform Likely To Move Up PhRMA Priority List
Executive Summary
The continued fallout from the Vioxx withdrawal is likely to make tort reform a higher priority for the Pharmaceutical Research & Manufacturers of America heading into 2005
You may also be interested in...
PhRMA Agenda For 2005 Includes Medicare Start-Up, Liability Reform
The Pharmaceutical Research & Manufacturers of America will be supporting medical malpractice reform measures at the state level as part of its agenda for 2005
PhRMA Agenda For 2005 Includes Medicare Start-Up, Liability Reform
The Pharmaceutical Research & Manufacturers of America will be supporting medical malpractice reform measures at the state level as part of its agenda for 2005
Merck "Parallel" R&D: Internal Programs Match External To Limit Uncertainty
Merck's practice of maintaining an internal research program parallel to any third-party collaboration guarantees an R&D project's survival should the external venture lose its funding, Merck Research Labs President Edward Scolnick, PhD, said.